MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising
SAN DIEGO–(BUSINESS WIRE)–Aug. 5, 2025– MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the Company”) today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy with the LTC treasury now valued at approximately $110.4 million as of August 4, 2025. MEI becomes the first U.S.-listed public company to adopt Litecoin as […]
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
SAN DIEGO–(BUSINESS WIRE)–Jul. 18, 2025– MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $3.42 per share, for expected aggregate […]
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
SAN DIEGO–(BUSINESS WIRE)–Jul. 22, 2025– MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has closed its previously announced private placement for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $3.42 per share, for aggregate gross proceeds of approximately $100 million. In connection with […]
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
Evaluation of Strategic Alternatives is Ongoing SAN DIEGO–(BUSINESS WIRE)–May 13, 2025– MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as […]
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
Evaluation of Strategic Alternatives is Ongoing SAN DIEGO–(BUSINESS WIRE)–Feb. 12, 2025– MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as […]